Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

"MariTide and all of the GLP-1 medications have similar side effect profiles: nausea, vomiting, abdominal pain, constipation and less commonly pancreatic irritation," says Dr. Nadler.

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

If MariTide achieves 22-23% weight loss in the phase 3 trial and CagriSema and retatrutide are in the 24-27% range which I estimated based on the available phase 2 data, I do not believe that the ...

Salim Syed has given his Hold rating due to a combination of factors surrounding Amgen’s recent data on MariTide, a potential treatment for obesity. The efficacy results from the 52-week Phase 2 ...

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Calling MariTide an “important breakthrough,” Susan Sweeney, Amgen’s executive vice president obesity and related conditions, said that beyond obesity and type 2 diabetes, the drug will also ...

Charlie CY Yang has given his Hold rating due to a combination of factors surrounding Amgen’s recent data release and market positioning. The data from the MariTide study in obesity, both with ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

Amgen investors are focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. The drug, given ...

By Katherine Hamilton Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug ...